According to a new lawsuit against the Drug Enforcement Administration [DEA], the agency is relying on scheduling standards that are arbitrary and misinterpret federal law to classify marijuana. The latest of many marijuana related lawsuits against the DEA, it has called into question the agency’s denial of prior cannabis rescheduling requests. The suit was filed in the U.S. Ninth Circuit Court of Appeals by the Scottsdale Research Institute [SRI].
The institute requested a review of the DEA’s scheduling determinations in 2020, 2016 and 1992 when the agency denied the petitions citing statutory obligations to maintain the status of cannabis as a Schedule 1 drug under the Controlled Substances Act. The petitioners also requested a review of the agency’s claims that marijuana must be strictly scheduled because according to the government, it currently has no acceptable medical value and has not been proven safe. Additionally, they argue that another statutory policy which the DEA says necessitates marijuana being strictly…
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.